RMRogier Mous

Rogier Mous

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rogier Mous has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Adequate synapse formation between leukemic B cells and effector T cells following stimulation with artificial TCR ligands

    by Rogier Mous, Philip Savage, Eric Eldering, Peter Teeling, Marinus Hj van Oers, René Aw van Lier

    Artificial T cell receptor (TCR) ligands can be used to direct virus-specific cytotoxic T lymphocytes (CTL) towards tumor cells. Because of their size, these constructs may differ from cognate peptides in their ability to induce T cell activation. We here analysed signalling outcomes upon synapse formation between human cytomegalovirus (CMV)-specific CTL and chronic lymphocytic leukemia (CLL) cells through targeted complexes (TC) containing anti-CD20 single-chain variable fragment and biotinylated major histocompatibility complex class I molecules presenting peptides from CMVpp65. TC coated CLL cells were effectively lysed by CMVpp65-specific CTL but induced less interferon gamma (IFN-γ) production than peptide loaded targets. Confocal microscopy revealed that TC induced a redistribution of TCR/CD3 but not CD2 towards the immunological synapse. Furthermore, morphological examination of immunological synapses showed smaller and ‘patchy’ interactions between TC coated B cells and CTL as compared with peptide coated targets. Finally, pre-incubation of CTL with CD2 antibodies led to an Fc-dependent redistribution of CD2 into TC-induced synapses and restored IFN-γ production by CMV-specific CTL. Thus, redistribution of CD2 towards the immunological synapse appears to be essential for full T cell activation. However, CD2 triggering is not required for efficient lysis of tumor cells, demonstrating that CTL require only minimal stimulation to release their cytotoxic content.


  • Open Access

    Redirection of CMV-specific CTL towards B-CLL via CD20-targeted HLA/CMV complexes

    by R Mous, P Savage, E B M Remmerswaal, R A W van Lier, E Eldering, M H J van Oers

    B-cell chronic lymphocytic leukaemia (B-CLL) is a slowly progressing malignancy of CD5+ B cells, for which at present no curative treatment is available. In our current study, we apply a novel bridging reagent to redirect cytomegalovirus (CMV)-specific cytotoxic T lymphocytes (CTL) to target B-CLL. A streptavidin-fused anti-CD20 single-chain variable fragment (scFv) is used in combination with biotinylated MHC class I molecules containing CMV pp65 peptide (HLA/CMV). We demonstrate that B-CLL cells coated with this CD20-HLA/CMV complex can be lysed by autologous CMV-specific CTL with similar efficiency as B-CLL cells directly loaded with CMV peptide. Killing is HLA restricted and occurs at scFv CD20 concentrations of ⩾ 100 ng ml−1 and HLA/CMV concentrations of ⩾ 20 ng ml−1. Furthermore, complex-coated B-CLL cells induce both proliferation and cytokine production (interferon γ, tumour necrosis factor α and macrophage inflammatory protein−1 β) in CMV-specific CD8+ T cells. Hereby, a necessary step towards possible application of CD20-HLA/CMV complexes for immunotherapy of B-cell malignancies is constituted.